Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

Elisa Gobbini; Anne Claire Toffart; Maurice Pérol; Jean Baptiste Assié; Michaël Duruisseaux; Dahna Coupez; Catherine Dubos; Virginie Westeel; Myriam Delaunay; Florian Guisier; Rémi Veillon; Valérie Gounant; Etienne Giroux Leprieur; François Roger Vanel; Nouha Chaabane; Eric Dansin; Hélène Babey; Chantal Decroisette; Fabrice Barlesi; Catherine Daniel; Pierre Fournel; Laura Mezquita; Youssef Oulkhouir; Anthony Canellas; Boris Duchemann; Olivier Molinier; Vincent Alcazer; Denis Moro-Sibilot; Matteo Giaj Levra

doi:10.1016/j.cllc.2020.04.013

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, Jean Baptiste Assié, Michaël Duruisseaux, Dahna Coupez, Catherine Dubos, Virginie Westeel, Myriam Delaunay, Florian Guisier, Rémi Veillon, Valérie Gounant, Etienne Giroux Leprieur, François Roger Vanel, Nouha Chaabane, Eric Dansin, Hélène Babey, Chantal Decroisette, Fabrice Barlesi, Catherine DanielPierre Fournel, Laura Mezquita, Youssef Oulkhouir, Anthony Canellas, Boris Duchemann, Olivier Molinier, Vincent Alcazer, Denis Moro-Sibilot, Matteo Giaj Levra

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

38 Citations (Scopus)

Résumé

Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non–small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score.

langue originale	Anglais
Pages (de - à)	e497-e510
journal	Clinical Lung Cancer
Volume	21
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.cllc.2020.04.013
état	Publié - 1 sept. 2020
Modification externe	Oui

Accès au document

10.1016/j.cllc.2020.04.013

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Gobbini, E., Toffart, A. C., Pérol, M., Assié, J. B., Duruisseaux, M., Coupez, D., Dubos, C., Westeel, V., Delaunay, M., Guisier, F., Veillon, R., Gounant, V., Giroux Leprieur, E., Vanel, F. R., Chaabane, N., Dansin, E., Babey, H., Decroisette, C., Barlesi, F., ... Levra, M. G. (2020). Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 21(5), e497-e510. https://doi.org/10.1016/j.cllc.2020.04.013

@article{458b545739bf4a5894b6edddcc09916b,

title = "Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients",

abstract = "Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non–small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score.",

keywords = "Efficacy, Immune checkpoint inhibitors, NSCLC, Re-challenge, Selection criteria",

author = "Elisa Gobbini and Toffart, {Anne Claire} and Maurice P{\'e}rol and Assi{\'e}, {Jean Baptiste} and Micha{\"e}l Duruisseaux and Dahna Coupez and Catherine Dubos and Virginie Westeel and Myriam Delaunay and Florian Guisier and R{\'e}mi Veillon and Val{\'e}rie Gounant and {Giroux Leprieur}, Etienne and Vanel, {Fran{\c c}ois Roger} and Nouha Chaabane and Eric Dansin and H{\'e}l{\`e}ne Babey and Chantal Decroisette and Fabrice Barlesi and Catherine Daniel and Pierre Fournel and Laura Mezquita and Youssef Oulkhouir and Anthony Canellas and Boris Duchemann and Olivier Molinier and Vincent Alcazer and Denis Moro-Sibilot and Levra, {Matteo Giaj}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.cllc.2020.04.013",

language = "English",

volume = "21",

pages = "e497--e510",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "5",

}

Gobbini, E, Toffart, AC, Pérol, M, Assié, JB, Duruisseaux, M, Coupez, D, Dubos, C, Westeel, V, Delaunay, M, Guisier, F, Veillon, R, Gounant, V, Giroux Leprieur, E, Vanel, FR, Chaabane, N, Dansin, E, Babey, H, Decroisette, C, Barlesi, F, Daniel, C, Fournel, P, Mezquita, L, Oulkhouir, Y, Canellas, A, Duchemann, B, Molinier, O, Alcazer, V, Moro-Sibilot, D & Levra, MG 2020, 'Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients', Clinical Lung Cancer, VOL. 21, Numéro 5, p. e497-e510. https://doi.org/10.1016/j.cllc.2020.04.013

TY - JOUR

T1 - Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

AU - Gobbini, Elisa

AU - Toffart, Anne Claire

AU - Pérol, Maurice

AU - Assié, Jean Baptiste

AU - Duruisseaux, Michaël

AU - Coupez, Dahna

AU - Dubos, Catherine

AU - Westeel, Virginie

AU - Delaunay, Myriam

AU - Guisier, Florian

AU - Veillon, Rémi

AU - Gounant, Valérie

AU - Giroux Leprieur, Etienne

AU - Vanel, François Roger

AU - Chaabane, Nouha

AU - Dansin, Eric

AU - Babey, Hélène

AU - Decroisette, Chantal

AU - Barlesi, Fabrice

AU - Daniel, Catherine

AU - Fournel, Pierre

AU - Mezquita, Laura

AU - Oulkhouir, Youssef

AU - Canellas, Anthony

AU - Duchemann, Boris

AU - Molinier, Olivier

AU - Alcazer, Vincent

AU - Moro-Sibilot, Denis

AU - Levra, Matteo Giaj

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non–small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score.

AB - Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non–small-cell lung cancer (NSCLC), yet no sufficient data support this strategy. Our retrospective study explored the efficacy of ICPi rechallenge in 144 advanced NSCLC patients. It might be an option in patients discontinuing the first ICPi for toxicity or clinical reasons, those able to maintain a treatment-free period, and those with a good Eastern Cooperative Oncology Group performance status score.

KW - Efficacy

KW - Immune checkpoint inhibitors

KW - NSCLC

KW - Re-challenge

KW - Selection criteria

UR - http://www.scopus.com/inward/record.url?scp=85087020142&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.04.013

DO - 10.1016/j.cllc.2020.04.013

M3 - Article

C2 - 32605892

AN - SCOPUS:85087020142

SN - 1525-7304

VL - 21

SP - e497-e510

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -